Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)

被引：0
|
作者：
Merriman, Joseph
Parikh, Kinjal
Tantravahi, Srinivas Kiran
Straubhar, Alli M.
Agarwal, Archana M.
Sendilnathan, Arun
Van Atta, Joan
Batten, Julia A.
Grossmann, Kenneth F.
Samlowski, Wolfram E.
Stenehjem, David D.
Agarwal, Neeraj
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Dept Pathol & ARUP Labs, Salt Lake City, UT USA
[3] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[4] Univ Utah, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4577
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts)
    Ernstoff, M. S.
    Regan, M. M.
    McDermott, D. F.
    Sosman, J. A.
    Dutcher, J. P.
    Clark, J. I.
    Crocenzi, T. S.
    Ochoa, A.
    Atkins, M. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Response to high-dose interleukin-2 (HD IL-2) therapy in patients with brain metastases from metastatic melanoma
    Powell, S. F.
    Dudek, A. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2
    David D. Stenehjem
    Michael Toole
    Joseph Merriman
    Kinjal Parikh
    Stephanie Daignault
    Sarah Scarlett
    Peg Esper
    Katherine Skinner
    Aaron Udager
    Srinivas Kiran Tantravahi
    David Gill
    Alli M. Straubhar
    Archana M. Agarwal
    Kenneth F. Grossmann
    Wolfram E. Samlowski
    Bruce Redman
    Neeraj Agarwal
    Ajjai Alva
    Cancer Immunology, Immunotherapy, 2016, 65 : 941 - 949
  • [34] Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2
    Stenehjem, David D.
    Toole, Michael
    Merriman, Joseph
    Parikh, Kinjal
    Daignault, Stephanie
    Scarlett, Sarah
    Esper, Peg
    Skinner, Katherine
    Udager, Aaron
    Tantravahi, Srinivas Kiran
    Gill, David
    Straubhar, Alli M.
    Agarwal, Archana M.
    Grossmann, Kenneth F.
    Samlowski, Wolfram E.
    Redman, Bruce
    Agarwal, Neeraj
    Alva, Ajjai
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (08) : 941 - 949
  • [35] A Pilot Study of Denileukin Diftitox (DD) in Combination With High-dose Interleukin-2 (IL-2) for Patients With Metastatic Renal Cell Carcinoma (RCC)
    Atchison, Elizabeth
    Eklund, John
    Martone, Brenda
    Wang, Lili
    Gidron, Adi
    Macvicar, Gary
    Rademaker, Alfred
    Goolsby, Charles
    Marszalek, Laura
    Kozlowski, James
    Smith, Norm
    Kuzel, Timothy M.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (07) : 716 - 722
  • [36] Durability of responses in patients with metastatic renal cell carcinoma treated with high dose lnterleukin-2 (HD IL-2)
    Clark, Joseph I.
    Morse, Michael A.
    Wong, Michael K. K.
    Mcdermott, David F.
    Kaufman, Howard L.
    Daniels, Gregory A.
    Perritt, Jessica C.
    Hua, Hong
    Aung, Sandra
    BJU INTERNATIONAL, 2015, 116 : 6 - 6
  • [37] Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma
    Lam, E. T.
    Lesinski, G.
    Mortazavi, A.
    Kendra, K. L.
    Carson, W. E., III
    Tahiri, S.
    Liersemann, R.
    Clinton, S. K.
    Olencki, T.
    Monk, J. P., III
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [38] Sequential Immune Monitoring of Melanoma and Renal Cell Carcinoma Patients Treated with High-dose Interleukin-2 (IL-2): Immune Patterns and Prognosis
    Foureau, D. M.
    Amin, A.
    Norton, H.
    Sarantou, T.
    McKillop, I. H.
    White, R. L.
    Salo, J. S.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S116 - S116
  • [39] HIGH-DOSE INTERLEUKIN-2 IN THE THERAPY OF METASTATIC RENAL-CELL CARCINOMA
    PARKINSON, DR
    SZNOL, M
    SEMINARS IN ONCOLOGY, 1995, 22 (01) : 61 - 66
  • [40] A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.
    Buchbinder, Elizabeth Iannotti
    Dutcher, Janice P.
    Perritt, Jessica C.
    Clark, Joseph
    Holtan, Shernan G.
    Kirkwood, John M.
    Curti, Brendan D.
    Lao, Christopher D.
    Kaufman, Howard
    Fishman, Mayer N.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345